Emergence of cardiac glycosides as potential drugs: Current and future scope for cancer therapeutics

Ranjith Kumavath, Sayan Paul, Honey Pavithran, Manash K. Paul, Preetam Ghosh, Debmalya Barh, Vasco Azevedo

Research output: Contribution to journalReview articlepeer-review


Cardiac glycosides are natural sterols and constitute a group of secondary metabolites isolated from plants and animals. These cardiotonic agents are well recognized and accepted in the treatment of various cardiac diseases as they can increase the rate of cardiac contractions by acting on the cellular sodium potassium ATPase pump. However, a growing number of recent efforts were focused on exploring the antitumor and antiviral potential of these compounds. Several reports suggest their antitumor properties and hence, today cardiac glycosides (CG) represent the most diversified naturally derived compounds strongly recommended for the treatment of various cancers. Mutated or dysregulated transcription factors have also gained prominence as potential therapeutic targets that can be selectively targeted. Thus, we have explored the recent advances in CGs mediated cancer scope and have considered various signaling pathways, molecular aberration, transcription factors (TFs), and oncogenic genes to highlight potential therapeutic targets in cancer management.

Original languageEnglish (US)
Article number1275
Issue number9
StatePublished - Sep 2021
Externally publishedYes


  • Cancer therapy
  • Cardiac glycosides
  • In vitro and in vivo anticancer activities
  • Therapeutic target
  • Transcription factors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Emergence of cardiac glycosides as potential drugs: Current and future scope for cancer therapeutics'. Together they form a unique fingerprint.

Cite this